Zhejiang Huahai Pharmaceutical Co., Ltd.

Zhejiang Huahai Pharmaceutical Co., Ltd. saw a notable stock decline today, contrasting with broader market trends. The company has faced challenges over the past year, including a significant drop in its stock value and high debt levels, reflecting ongoing pressures in the pharmaceuticals sector.

Zhejiang Huahai Pharmaceutical Co., Ltd. experienced notable intraday gains, contrasting with a decline in the broader market. The company has shown strong weekly and monthly performance, yet faces long-term challenges, including a significant one-year decline and high debt levels, raising concerns about its growth prospects.

Zhejiang Huahai Pharmaceutical Co., Ltd. saw a significant intraday increase on June 29, 2026, amid a rising Shanghai Composite. However, the company has struggled over the past year, with a notable decline in stock value compared to the market, highlighting ongoing financial challenges despite recent gains.

Zhejiang Huahai Pharmaceutical Co., Ltd. faced a significant stock decline, contrasting with the broader market's modest gains. The company has struggled over the past week and year, showing a decrease in net sales and facing challenges such as a high debt-to-equity ratio and low return on equity.

Zhejiang Huahai Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with a modest gain in the China Shanghai Composite. The company faces financial challenges, including a high debt-to-equity ratio and declining net sales, indicating a need for strategic reassessment despite its large market capitalization.

Zhejiang Huahai Pharmaceutical Co., Ltd. saw a significant intraday increase on March 27, 2026, contrasting with the broader market's modest gains. Despite a recent positive trend, the company has struggled with long-term growth, reporting low returns and financial metrics indicating a high valuation relative to earnings.

Zhejiang Huahai Pharmaceutical Co., Ltd. saw a significant intraday gain, contrasting with its recent longer-term declines. Over the past year, the company has underperformed the market, with key financial metrics indicating challenges, including a relatively high valuation and modest return on equity. Its market capitalization stands at CNY 22,852 million.

Zhejiang Huahai Pharmaceutical Co., Ltd. faced a notable decline in its stock today, contrasting with broader market trends. The company has struggled over the past week and month, with significant annual and year-to-date losses. Financial metrics indicate high debt levels and low return on equity, raising concerns about its stability.

Zhejiang Huahai Pharmaceutical Co., Ltd. faced a significant stock decline, reflecting ongoing performance challenges. The company reported a decrease in net sales and operating profit, alongside a high debt-to-equity ratio. Its financial indicators suggest a difficult market environment, despite a modest dividend yield.

Zhejiang Huahai Pharmaceutical Co., Ltd. saw a significant intraday increase on March 6, 2026, contrasting with the modest gain of the China Shanghai Composite. However, the company's long-term performance reveals challenges, including a decline in net sales and negative operating profit growth, despite its large market capitalization.

Zhejiang Huahai Pharmaceutical Co., Ltd. faced a decline in stock value, reflecting ongoing challenges. The company has experienced significant long-term hurdles, including a high debt-to-equity ratio and decreasing net sales and operating profit. These factors contribute to its underperformance relative to broader market trends.